Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 110.9% in February

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 29,100 shares, an increase of 110.9% from the February 13th total of 13,800 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average trading volume of 374,100 shares, the days-to-cover ratio is currently 0.1 days.

Coeptis Therapeutics Stock Up 5.8 %

Shares of NASDAQ COEP traded up $0.61 during midday trading on Friday, hitting $11.06. 35,263 shares of the stock traded hands, compared to its average volume of 147,536. The company has a market cap of $35.86 million, a PE ratio of -1.91 and a beta of -0.77. Coeptis Therapeutics has a one year low of $2.31 and a one year high of $13.70. The business has a 50 day moving average price of $10.48 and a two-hundred day moving average price of $6.15. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.40 and a current ratio of 0.40.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.